Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00399464 | Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia | PHASE3 | COMPLETED | 1,177 | — | — | Nov 1, 2006 | Oct 1, 2007 | Oct 2, 2009 | 1 | Japan |
| NCT00290030 | ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH | PHASE3 | COMPLETED | 800 | — | — | May 1, 2001 | Oct 1, 2004 | Mar 12, 2009 | - | — |
| Name | Type | Description |
|---|---|---|
| alfuzosin | DRUG | - |
Inclusion Criteria: * Japanese; * Having a symptomatic BPH diagnosed clinically by digital rectal examination and ultrasonography within the last 6 months; * Suffering for at least 6 months from lower urinary tract symptoms related to BPH. Exclusion Criteria: * Patients with mental disorders or w...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Boston Scientific Corporation | BSX | 2 | — | Undisclosed |
| PROCEPT BioRobotics Corp. | PRCT | 2 | NA | Undisclosed |
| EDAP TMS SA Sponsored ADR | EDAP | 1 | NA | Undisclosed |
| Profound Medical Corp | PROF | 1 | — | Undisclosed |